Microbix Biosystems Inc. (MBX) — closed signal from December 6, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on March 6, 2026.
Predicted vs. what happened
What happened
Hit or exceeded the predicted growth inside the window.
The thesis — published December 6, 2025
Microbix is a small biotech with recent corporate moves that could lift the stock but it is risky. The company is buying back shares and teamed up with Seegene Mexico, which may boost demand for its testing products. At the same time, a fund sold a related MBX position, showing the stock can move sharply and be hard to trade.
Primary drivers
- Models show better sentiment than the market, helping price momentum.
- Buyback and Seegene deal should increase short-term demand.
- Very strong sentiment readings raise chance of a sharp squeeze.
- Name confusion and fund selling increase liquidity and stock-specific risk.
How it played out
MBX: peak stayed below target, then faded
Lyra published MBX at 31.97 on 2025-12-06, with 42% expected growth and a 45.40 target. The thesis pointed to a buyback, the Seegene Mexico deal, stronger sentiment than the market, and the chance of a sharp squeeze. It also flagged name confusion, fund selling, liquidity risk, and stock-specific risk.
Inside the window, MBX rose to 44.89 on 2026-01-15, a 40.4% peak gain. It stayed below the target. By 2026-03-06, it ended at 30.55. The thesis partly played out on price strength, but the target was missed.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.